Bydd peth cynnydd yn digwydd cyn yr adolygiad. Comisiynodd Ysgrifennydd y Cabinet dros Iechyd, Llesiant a Chwaraeon a minnau Iechyd Cyhoeddus Cymru i sefydlu grŵp arbenigol annibynnol ar HIV yng Nghymru. Bydd y grŵp yn adolygu'r dystiolaeth o ran pa mor effeithiol yw cyffuriau proffylactig cyn-gysylltiol (PrEP) wrth atal HIV a'r goblygiadau ar gyfer cael heintiau eraill a drosglwyddir yn rhywiol. Ni fydd yr adolygiad hwn yn mesur yr effeithiolrwydd clinigol yn erbyn y costau gan mai gwaith Grŵp Strategaeth Feddyginiaethau Cymru yw hyn. Fodd bynnag, mae’r grŵp arbenigol wedi cael cais i roi darlun cynnar o natur arloesol ac, o bosib, drawsnewidiol y feddyginiaeth. Disgwylir cael argymhellion y grŵp arbenigol erbyn diwedd 2016.
There are some actions that are progressing in advance of that review. The Cabinet Secretary for Health, Well-being and Sport and I recently commissioned Public Health Wales to establish an independent HIV expert group in Wales. The group will review the evidence of the effectiveness of PrEP (pre-exposure prophylaxis) drugs in HIV prevention and the implications for the acquisition of other sexually transmitted infections. This review will not measure the clinical effectiveness against the costs which is the role of the All Wales Medicines Strategy Group (AWMSG), however, it has been asked to give an early indication of the innovative and potentially transformative nature of the medicine. Recommendations from the expert group are expected by the end of 2016.